Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Patent
1995-10-16
1999-07-06
Hutzell, Paula K.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
424 946, 4242781, 4241841, 4241921, 4242361, 4242471, 4242341, 530300, 530350, 530825, 514 2, A61K 3908, A61K 3846
Patent
active
059194634
ABSTRACT:
The invention features methods and compositions for inducing protective and/or therapeutic immune responses to an antigen in a mammal. In these methods, an antigen is administered to the mammal with a toxin of a Clostridium (e.g., C. difficile), or a fragment or derivative thereof having adjuvant activity.
REFERENCES:
patent: 4713240 (1987-12-01), Wilkins et al.
patent: 4863852 (1989-09-01), Wilkins et al.
patent: 5098826 (1992-03-01), Wilkins et al.
patent: 5182109 (1993-01-01), Tamura et al.
Bartoloni, et al., "Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide", Vaccine 13:463-470 (1995).
Davin et al., H. pylori Urease Elicits Protection Against H. felis Infection in Mice, Gastroenterology 104:A1035 (Apr. 1993).
Pallen and Clayton, Vaccination Against Helicobacter pylori Urease, The Lancet 336:186-187, 1990.
Allo et al., Prevention of Clindamycin-Induced Colitis in Hamsters by Clostridium sordellii Antitoxin, Gastroenterology 76:351-355, 1979.
Almeida et al., Immune Response to Nasal Delivery of Antigenically Intact Tetanus Toxoid Associated with Poly(L-lactic acid) Microspheres in Rats, Rabbits and Guinea-pigs, J. Pharm. Pharmacol. 45:198-203, 1993.
Barroso et al., Mutagenesis of the Clostridium difficile Toxin B Gene and Effect on Cytotoxic Activity, Microbial. Pathogenesis 16:297-303, 1994.
Barroso et al., Nucleotide Sequence of Clostridium difficile Toxin B Gene, Nucleic Acids Research 18:4004, 1990.
Bette et al., A Comparative Biochemical, Pharmacological and Immunological Study of Clostridium Novyi .alpha.-Toxin, C. Difficile Toxin B and C. Sordellii Lethal Toxin, Toxicon 29:877-887, 1991.
Budai, Intestinal Infections: Current Aspects and New Possibilities of Prophylaxis and Treatment, Ther. Hung. (Hungary) 37(1):3-16, 1989.
Burnette et al., Site-Specific Mutagenesis of the Catalytic Subunit of Cholera Toxin: Substituting Lysine for Arginine 7 Causes Loss of Activity, Infection and Immunity 59:4266-4270, 1991.
Corthier et al., Protection Against Experimental Pseudomembranous Colitis in Gnotobiotic Mice by Use of Monoclonal Antibodies Against Clostridium difficile Toxin A, Infection and Immunity 59:1192-1195, 1991.
Cryz Jr. et al., Human Immunodeficiency Virus-1 Principal Neutralizing Domain Peptide-toxin A conjugate Vaccine, Vaccine 13:67-71, 1995.
Czerkinsky et al., Oral Administration of a Streptococcal Antigen Coupled to Cholera Toxin B Subunit Evokes Strong Antibody Responses in Salivary Glands and Extramucosal Tissues, Infection & Immunity 57:1072-77, 1989.
Daubener et al., Clostridium difficile Toxins A and B Inhibit Human Immune Response In Vitro, Infection and Immunity 56:1107-1112, 1988.
Dellert and Cohen, Diarrheal Disease Established Pathogens, New Pathogens, and Progress in Vaccine Development, Pediatric Gastroenterology 23:637-654, 1994.
Dove et al., Molecular Characterization of the Clostridium difficle Toxin A Gene, Infection and Immunity 58:480-488, 1990.
Dubos et al., Immediate Postnatal Inoculation of a Microbial Barrier to Prevent Neonatal Diarrhea Induced by Clostridium difficile in Young Conventional and Gnotobiotic Hares, Am. J. Vet. Res. 45:1242-1244, 1984.
Fernie et al., Active and Passive Immunization to Protect Against Antibiotic Associated Caecitis in Hamsters, Develop. biol. Standard 53:325-332, 1983.
Field et al., Intestinal Electrolyte Transport and Diarrheal Disease, New England Journal of Medicine 321:879-883, 1989.
Flegel et al., Cytokine Response by Human Monocytes to Clostridium difficile Toxin A and Toxin B, Infection and Immunity 59:3659-3666, 1991.
Frey and Wilkins, Localization of Two Epitopes Recognized by Monoclonal Antibody PCG-4 on Clostridium difficile Toxin A, Infection and Immunity 60:2488-2492, 1992.
Gordon and Leppla, Proteolytic Activation of Bacterial Toxins: Role of Bacterial and Host Cell Proteases, Infect. Immun. 62:333-340, 1994.
Grant et al., Role of Trypsin-Like Cleavage at Arginine 192 in the Enzymatic and Cytotonic Activities of Escherichia coli Heat-Labile Enterotoxin, Infect. Immun. 62:4270-4278, 1994.
Holmgren et al., Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems, Vaccine 11:1179-1183, 1993.
Kim et al., Immunization of Adult Hamsters against Clostridium difficile-Associated Ileocecitis and Transfer of Protection to Infant Hamsters, Infect. Immun. 55:2984-2992, 1987.
Liang et al., Oral Administration of Cholera Toxin-Sendai Virus Conjugate Potentiates Gut and Respiratory Immunity Against Sendai Virus, J. Immunol. 141:1495-1501, 1988.
Libby et al., Effects of the Two Toxins of Clostridium difficile in Antibiotic-Associated Cecitis in Hamsters, Infect. Immun. 36:822-829, 1982.
Lyerly et al., Vaccination against Lethal Clostridium difficile Enterocolitis with a Nontoxic Recombinant Peptide of Toxin A, Current Microbiology 21:29-32, 1990.
Malorni et al., Enhancement of Cell-Mediated Cytotoxicity by Clostridium Difficile Toxin A: An In Vitro Study, Toxicon 29:417-428, 1991.
McGhee and Kiyono, New Perspectives in Vaccine Development: Mucosal Immunity to Infections, Infectious Agents and Disease 2:55-73, 1993.
McGhee et al., The mucosal immune system: from fundamental concepts to vaccine development, Vaccine 10:75-88, 1992.
Okamoto et al., Effect of Substitution of Glycine for Arginine at Position 146 of the A1 Subunit on Biological Activity of Escherichia coli Heat-Labile Enterotoxin, J. Bacteriology 170:2208-2211, 1988.
Pothoulakis et al., Clostridium difficile Toxin A Stimulates Intracellular Calcium Release and Chemotactic Response in Human Granulocytes, J. Clin. Invest. 81:1741-1745, 1988.
Price et al., Cloning of the Carbohydrate-binding Portion of the Toxin A Gene of Clostridium difficile, Current Microbiology 16:55-60, 1987.
Sansonetti, Escherichia coli, Shigella, antibiotic-associated diarrhea, and prevention and treatment of gastroenteritis, Current Opinion in Infect. Diseases 5:66-73, 1992.
Siffert et al., Effects of Clostridium difficile Toxin B on Human Monocytes and Macrophages: Possible Relationship with Cytoskeletal Rearrangement, Infect. Immun. 61:1082-1090, 1993.
Silva, Update on Pseudomembranous Colitis, West J. Med. 151:644-648, 1989.
Spangler, Structure and Function of Cholera Toxin and the Related Escherichia coli Heat-Labile Enterotoxin, Microbiological Reviews 56:622-647, 1992.
Tamura et al., Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount to the holotoxin as an adjuvant for nasal influenza vaccine, Vaccine 12:1083-1089, 1994.
Trnka and Lamont, Clostridium difficile Colitis, Advances in Internal Medicine 29:85-107, 1984.
Xu-Amano et al., Helper T Cell Subsets for Immunoglobulin A Responses: Oral Immunization with Tetanus . . . Induces Th2 Cells in Mucosa Associated Tissues, J. Exp. Med. 178:1309-1320, 1993.
Lee et al., Oral Immunization with Recombinant Helicobacter pylori Urease Induces Secretory IgA Antibodies and Protects Mice from Challenge with Helicobacter felis, J. Infectious Disease 172:161-172, 1995.
Lyerly et al., Purification and Properties of Toxins A and B of Clostridium difficile, FEMS Microbiology Letters 33:31-35, 1986.
Michetti et al. (1994) Gastroenterology. vol. 107, 1002-1011.
Holmgren et al. (1994) Am. J. Trop. Med. Hyg. vol. 50(5) Suppl. 42-54.
Torres et al. (1995) Infection and Immunity. vol. 63(12)4619-4627.
Lei Wende
Lyerly David M.
Monath Thomas P.
Moncrief James S.
Thomas, Jr. William D.
Hutzell Paula K.
Masood Khalid
OraVax, Inc.
LandOfFree
Clostridium difficle toxins as mucosal adjuvants does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Clostridium difficle toxins as mucosal adjuvants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Clostridium difficle toxins as mucosal adjuvants will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-897330